This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vaidyanathan, G. Articles by Zalutsky, M. R. Search for Related Content PubMed PubMed Citation Articles by Vaidyanathan, G. Articles by Zalutsky, M. R.

5-[²¹¹At]Astato-2'-deoxyuridine, an -Particle-emitting Endoradiotherapeutic Agent Undergoing DNA Incorporation¹

Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710

When labeled with the subcellular range Auger electron emitters ¹²⁵I and ¹²³I, the thymidine analogue 5-iodo-2'-deoxyuridine (IUdR) is highly cytotoxic but only to cells going through S-phase during exposure to these radiopharmaceuticals. Since ²¹¹At emits -particles of high linear energy transfer, but with a range of a few cell diameters, an IUdR analogue labeled with ²¹¹At could markedly improve the homogeneity of tumor dose deposition. Herein we describe the synthesis of 5-[²¹¹At]astato-2'-deoxyuridine ([²¹¹At]AUdR) in 85–90% radiochemical yield via the astatodestannylation of 5-(trimethylstannyl)-2'-deoxyuridine. In vitro studies using the human glioma cell line D-247 MG demonstrated that [²¹¹At]AUdR was virtually identical to [¹³¹I]IUdR; both exhibited a linear increase in cell uptake with activity concentration, an inhibition of uptake by 10 µM IUdR, and the incorporation of about 50% of cell-bound activity into DNA. In a clonogenic assay, [²¹¹At]AUdR exhibited a high cytotoxicity for D-247 MG cells, with a D₀ equivalent to less than 3 ²¹¹At atoms/cell.

¹ Supported in part by Grants CA 42324 and NS 20023 from the NIH.

² To whom requests for reprints should be addressed, at Department of Radiology, Box 3808, Duke University Medical Center, Durham, NC 27710. Phone: (919) 684-7708; Fax: (919) 684-7121.

Received 12/ 7/95. Accepted 1/31/96.

This article has been cited by other articles:

				E. S. Semnani, K. Wang, S. J. Adelstein, and A. I. Kassis 5-[123I/125I]Iodo-2'-Deoxyuridine in Metastatic Lung Cancer: Radiopharmaceutical Formulation Affects Targeting J. Nucl. Med., May 1, 2005; 46(5): 800 - 806. [Abstract] [Full Text] [PDF]

				O. R. Pozzi and M. R. Zalutsky Radiopharmaceutical Chemistry of Targeted Radiotherapeutics, Part 1: Effects of Solvent on the Degradation of Radiohalogenation Precursors by 211At {alpha}-Particles J. Nucl. Med., April 1, 2005; 46(4): 700 - 706. [Abstract] [Full Text] [PDF]

				J. G. Tjuvajev, M. Doubrovin, T. Akhurst, S. Cai, J. Balatoni, M. M. Alauddin, R. Finn, W. Bornmann, H. Thaler, P. S. Conti, et al. Comparison of Radiolabeled Nucleoside Probes (FIAU, FHBG, and FHPG) for PET Imaging of HSV1-tk Gene Expression J. Nucl. Med., August 1, 2002; 43(8): 1072 - 1083. [Abstract] [Full Text] [PDF]

				M. R. Zalutsky, X.-G. Zhao, K. L. Alston, and D. Bigner High-Level Production of {alpha}-Particle-Emitting 211At and Preparation of 211At-Labeled Antibodies for Clinical Use J. Nucl. Med., October 1, 2001; 42(10): 1508 - 1515. [Abstract] [Full Text] [PDF]